BRCA2 Heterozygosity Delays Cytokinesis in Primary Human Fibroblasts
Background: Inherited mutations in the tumour suppressor gene BRCA2 greatly increase the risk of developing breast, ovarian and other types of cancers. So far, most studies have focused on the role of BRCA-pathways in the maintenance of genomic stability.
Main Authors: | Jonsdottir, Asta Björk, Vreeswijk, Maaike P. G., Wolterbeek, Ron, Devilee, Peter, Tanke, Hans J., Eyfjörd, Jorunn E., Szuhai, Karoly |
---|---|
Format: | Online |
Language: | English |
Published: |
IOS Press
2009
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618909/ |
Similar Items
-
The Icelandic founder mutation BRCA2 999del5: analysis of expression
by: Mikaelsdottir, Evgenia K, et al.
Published: (2004) -
Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13.
by: Cleton-Jansen, A. M., et al.
Published: (1995) -
Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma.
by: Bièche, I., et al.
Published: (1997) -
Mechanisms of increased risk of tumorigenesis in Atm and Brca1 double heterozygosity
by: Wang, Jufang, et al.
Published: (2011) -
Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer
by: Birgisdottir, Valgerdur, et al.
Published: (2006)